What are the most serious adverse reactions of dasatinib?

Dasatinib (Dasatinib) is a targeted therapy used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) and is generally effective and safe. However, like other medicines, dasatinib may cause some adverse reactions, some of which may be serious. Patients and physicians should pay close attention to these adverse reactions during use of dasatinib and take appropriate measures to mitigate or manage them.

1.Pulmonary arterial hypertension (PAH): Pulmonary arterial hypertension is one of the serious adverse reactions that may be caused by dasatinib. In some cases, patients developed symptoms related to PAH, such as dyspnea, chest pain, palpitations, etc. after taking dasatinib. Therefore, patients should receive periodic cardiac function assessment and monitoring for pulmonary hypertension while taking dasatinib.

2.Cardiotoxicity:Dasatinib (Startax) may also cause cardiotoxicity, manifesting as arrhythmia, angina, heart failure and other symptoms. Patients should receive regular electrocardiograms and cardiac function assessments and be monitored for the emergence of cardiovascular symptoms while taking dasatinib.

3.Bleeding: Dasatinib (Startase) may cause bleeding during use, including severe bleeding such as gastrointestinal bleeding, cerebral hemorrhage, etc. Therefore, patients should closely monitor bleeding symptoms and seek medical treatment in a timely manner while taking Dasatinib (Startax).

4.Fluid retention: Fluid retention is one of the common adverse reactions of dasatinib (Startase) , which may lead to edema, dyspnea and other symptoms. Patients should be closely monitored for changes in weight and edema while taking dasatinib (Startax) and adjust fluid management as needed.

5.Abnormal liver function:Dasatinib (Startase)It may lead to abnormal liver function, manifested by symptoms such as elevated liver enzymes and jaundice. Patients should undergo regular liver function tests and monitor changes in liver function while taking dasatinib (Startax).

6.Thrombocytopenia:Dasatinib (Tasatinib) may cause thrombocytopenia during use and increase the risk of bleeding. Therefore, patients should closely monitor platelet counts and take appropriate measures to prevent bleeding while taking dasatinib.

7.Infection: Becausedasatinib (Startax) may suppress immune system function, patients may be more susceptible to infection during use. Therefore, patients should take precautions to avoid infection and seek prompt medical treatment for any symptoms of infection.

8.Musculoskeletal system toxicity:Dasatinib (Startase) may cause musculoskeletal system toxicity during use, including symptoms such as muscle pain and joint pain. Patients should promptly report these symptoms to their doctor and adjust their treatment plan as needed.

9.Visual problems:Dasatinib (Startase) may cause vision problems during use, such as blurred vision, dry eyes, etc. Patients should pay close attention to changes in vision and seek medical treatment promptly.

10.Other adverse reactions: In addition to the above-mentioned adverse reactions, Dasatinib (Startase) may also cause other adverse reactions, such as nausea, vomiting, diarrhea, fatigue, etc. Patients should pay close attention to these symptoms and seek help from their doctor.

In summary, although dasatinib (Startax) is an important anticancer drug, its use may cause some serious adverse reactions. Patients should closely monitor the occurrence of adverse reactions during the use of Dasatinib and seek medical treatment in a timely manner to ensure safe and effective treatment. At the same time, patients and doctors should work closely together to formulate personalized treatment plans to minimize the occurrence and impact of adverse reactions.